

Content available at: <https://www.ipinnovative.com/open-access-journals>

IP International Journal of Medical Microbiology and Tropical Diseases

Journal homepage: <https://www.ijmmttd.org/>

Original Research Article

Frequency of candida infection among intensive care unit patients and their susceptibility profile

Ayushi Jain¹, Umar Farooq^{1,*}, Sudhir Singh¹, Vasundhara Sharma¹, Shweta R Sharma¹, Imran Ahamad¹¹Dept. of Microbiology, Teerthanker Mahaveer Medical College and Research Center, Moradabad, Uttar Pradesh, India

ARTICLE INFO

Article history:

Received 03-08-2021

Accepted 12-08-2021

Available online 01-09-2021

Keywords:

Candida species

Non-albicans candida

Antifungal Susceptibility Testing

ABSTRACT

Background: *Candida* species are responsible for causing many health care associated and central line associated infections. They are responsible for causing opportunistic infection in human beings. Genus of *Candida* is composed of a heterogeneous group of organisms. Invasive infections of *Candida* mainly caused by *Candida albicans*, *Candida glabrata*, *Candida parapsilosis* & *Candida tropicalis*.

Aim and objective: The main objective of this study was to isolate *Candida albicans* and Non-albicans *Candida* and their antifungal susceptibility testing.

Materials and Methods: The study was carried out in the Department of Microbiology, in Tmu Hospital Moradabad. Total numbers of 806 clinical samples were processed in which 206 isolates were taken for *Candida*. Isolation and antifungal susceptibility testing done by Vitek-2 system.

Result: Out of 206 samples 77(37%) were *C. albicans* and 129(63%) were Non-albicans *Candida* (NAC). Maximum isolated species were *C. albicans* 77(37%), followed by *C. tropicalis* 70(34%), *C. parapsilosis* 24(12%), *C. glabrata* 19(9%), *C. dubliniensis* 12(6%), *C. krusei* 3(1%), *C. africana* 1(1%).

Conclusion: Infection caused by NAC species have increased. *C. tropicalis* was the most common isolated species. *Candida albicans*, *C. glabrata* and *C. krusei* were shown high susceptibility to fluconazole and voriconazole. Amphotericin B, Caspofungin, Micafungin and Flucytosine shows high susceptibility towards other *Candida* species.

This is an Open Access (OA) journal, and articles are distributed under the terms of the [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License](https://creativecommons.org/licenses/by-nc-sa/4.0/), which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: reprint@ipinnovative.com

1. Introduction

Incidence of fungal infections has been arising globally and found most commonly caused by *Candida* species. *Candida* species are responsible for causing many health care associated and central line associated infections.¹

Nosocomial infections are concerned more with medical device leading to dreadful consequences like systemic infection that could be life taking, also complicated by destruction of internal tissue.² Mortality rate is 50% in patients of blood stream infection.³

Among Human immunodeficiency virus (HIV) patients and other immunocompromised patients oral candidiasis is very commonly caused by *Candida albicans*.⁴ In women it colonizes genital area causing vaginal candidiasis leading to vaginal thrush.

Even though researchers have pointed out that *Candida* might be causative factor for mucositis of digestive tract, part played by catheter in patients with unusual lower number of neutrophils is still not understood in comparison to patients of intensive care unit (ICU).⁵

The cases of infection caused by *Candida albicans* have been reduced in number but rate of Non-albicans species have been increased.⁶

* Corresponding author.

E-mail address: farooqzf@yahoo.com (U. Farooq).

Antifungal resistance by non-albicans *Candida* provisions the quick, early and accurate identification and is vital because of an increase in evidence of epidemiological shift of causative agents from *C.albicans* to non-albicans *Candida*.⁷

2. Material and Methods

The study was carried out in the Department of Microbiology, in Tmu Hospital Moradabad.

Total numbers of 806 clinical samples were processed in which 206 isolates were taken for *candida*. Sample was collected from various ICU's and various other clinical departments of the hospital. The different clinical specimens like blood, E.T aspirates, BAL fluid, throat swab, urine, high vaginal swab, Foley's catheter tip and Venous catheters were taken.

2.1. Sample Processing

1. Respiratory samples were inoculated on Blood Agar and SDA. Urine samples were inoculated on CLED Agar and incubated at 37⁰ for 24-48 hrs.
2. The collected blood samples were inoculated into the culture bottle for blood culture and positive blood culture were indicated by change in the color on the screen of BacT ALERT 3D.⁸
3. Positive blood culture were proceeded for subculture and were incubated at 37⁰temp for 24-48 hrs .
4. Colonies have been identified on the basis of colony morphology and culture characteristics. After gram's staining Speciation and Antifungal sensitivity pattern was done by Vitek-2 system.

2.2. Identification & Antifungal Suceptibility Testing

Identification, speciation and antifungal susceptibility of *Candida* species was done by automated method.

Identification of *Candida* species was done by VITEK 2 with 2 YST Card & antifungal susceptibility was done with VITEK 2 AST-YSO7 Card.⁸

2.3. Sample preparation⁹

1. 24hr old culture was tested. Cassette of Vitek 2 compact labeled with barcode was selected and the no. of cassette were defined.
2. In the cassette, polystyrenes tube was placed and 3ml of Vitek saline was taken in these tubes.
3. After that by using sterile loop the isolated colonies were emulsified in Vitek saline. A uniform suspension was made.
4. Inoculum was checked by Densicheck plus. McFarland standard (Vitek 2.20 YST and Vitek 2 YST Card) was checked by Densicheck.
5. Cards were prepared for inoculation.

6. Pre-inserted Vitek 2.20 YST Vitek 2 YST Card, were transferred into selected polystyrene tubes from the corresponding suspension.
7. Then all the prepared inoculums in cassette were loaded into the instrument in filler section.

2.4. Loading of sample

Prepared Cassette were loaded into the filler section of instrument, after that door was closed.

The User Interface Screen was pressed and it was completed in 70seconds cycle. Blue indicator light was flashed when the filling cycle was completed. Cassette was removed from the filler section and loaded into the load section within 10 minutes. Barcodes were scanned & checked against the maintain Virtual Cassette electronic work list. Straws were cut and taped up. Finally, Cards were loaded into carousel.

The cassette wastes were discarded and it was indicated by flashing blue arrow on the instrument. The loading was completed.

2.5. Result reading

The result generated as genus-level, group-level identification, while Vitek 2 AST-YSO7 Card estimates the sensitivity and resistance to Fluconazole, Voriconazole, Amphotericin B, Micafungin, Caspofungin and Flucytosine.

3. Result

The samples were obtained from the patients admitted in ICU's of Hospital. Out of 806, total 206 *Candida* isolate from various clinical specimen from different ward of intensive Care Unit.

Table 1: Showing out of 206 (100%) samples 77 (37%) were *C.albicans* and 129 (63%) were NAC.

Species	Number	Percentage
<i>C.albicans</i>	77	37%
NAC	129	63%
Total	206	100%

Table 2: Showing Sex wise distribution. The *Candida* infection were more in male in contrast to female.

Sex	Number	Percentage
Male	(n=140)	68%
Female	(n=66)	32%
Total	(n=206)	100%

Maximum isolated species were *C.albicans* 77(37%), followed by *C. tropicalis* 70(34%), *C. parapsilosis* 24(12%), *C. glabrata* 19(9%), *C. dubliniensis* 12(6%) ,*C. krusei* 3(1%), *C.african* 1(1%).

Table 3: Sensitivity of *C.albicans* to amphotericin-B was 92%, 90% to Caspofungin, 84% to Micafungin, 78% to Flucytosine, 66% to voriconazole and least sensitive 50% to fluconazole. Sensitivity of *C. tropicalis* to Amphotericin-B, Micafungin, and Caspofungin was 100%, 97% to Flucytosine, 91% to fluconazole and voriconazole. *C. glabrata* showed 89% sensitivity towards Amphotericin-b & Flucytosine, 79% to Caspofungin and Micafungin, 13% to voriconazole, 12% to fluconazole. *C. parapsilosis* showed 100% sensitivity towards Caspofungin, Micafungin, Amphotericin-B and Flucytosine. Sensitivity of *C. dubliniensis* to amphotericin-b was 100%, 91% to fluconazole, voriconazole, Micafungin, Caspofungin and Flucytosine. *C. krusei* was resistant to fluconazole, 67% sensitive to amphotericin-b, Micafungin, Caspofungin and Flucytosine, 33% was sensitive to voriconazole. *C.african* showed 100% sensitivity to azole group, Amphotericin-B, Micafungin, Caspofungin & Flucytosine.³

Species (No.)	Fluconazole No.(%)	Voriconazole No.(%)	Caspofungin No.(%)	Micafungin No.(%)	Amphotericin-B No.(%)	Flucytosine No.(%)
<i>C.albicans</i> (n=77)	50(65%)	51(66%)	69(90%)	65(84%)	71(92%)	60(78%)
<i>C. tropicalis</i> (n=70)	64(91%)	64(91%)	70(100%)	70(100%)	70(100%)	68(97%)
<i>C.glabrata</i> (n=19)	12(63%)	13(68%)	15(79%)	15(79%)	17(89%)	17(89%)
<i>C. parapsilosis</i> (n=24)	23(95%)	22(91%)	24(100%)	24(100%)	24(100%)	24(100%)
<i>C. dubliniensis</i> (n=12)	11(91%)	11(91%)	11(91%)	12(100%)	11(91%)	11(91%)
<i>C.krusei</i> (n=03)	00	01(33%)	02(67%)	02(67%)	02(67%)	02(67%)
<i>C.african</i> (n=01)	01(100%)	01(100%)	01(100%)	01(100%)	01(100%)	01(100%)




Fig. 1: Pie chart showing distribution of species of *Candida*.

4. Discussion

Infection caused by *Candida* has been increasing gradually. *Candida* species normally present as commensal of the human body but capable of causing opportunistic infection especially in immunocompromised individual.¹⁰

Although, infection caused by *C. albicans* is very common but recently infection of NAC is increasing. NAC species are gaining importance in recent years because they show resistance to antifungal drugs. In our study, percentage of non albicans *Candida* (62.6%) was higher than *Candida albicans* (37%). Identical study was conducted by Sundaram M et al⁹ concluded that NAC (57%) was higher than *C.albicans* (43%). While in a study conducted by Lerory O et al¹¹ *C. albicans* (57.0%) were

isolated more as compared to Non-albicans *Candida*.

In our present study albicans isolated was 37% and in NAC most commonly isolated species was *C. tropicalis* (33.9%) followed by *C. parapsilosis* (11.6%), *C. glabrata* (9.2%), *C. dubliniensis* (5.8%), *C. krusei* (1.4%) and *C.african* (0.4%). A study done by Ahmad I et al¹² had similar percentage that *C.albicans* isolated was 36% and in NAC most commonly found species was *C. tropicalis* (40%) followed by *C. glabrata* (10%), *C. dubliniensis* (9%) and *C. krusei* (2%).

Our study showed that the rate of *Candida* infection were more in male 67% than in female 36%. This result is comparable with other study conducted by Yashavanth R. at el¹³ where 62.12% of *Candida* was isolated in male and 37.87% in female. this is contrast to the study conducted by Kauffman C et al.¹⁴ which showed *Candida* were more isolated in female 54.7% than male 45.3%.

In our study, *C.albicans* showed 35%, 34%, 22% resistance to fluconazole, voriconazole and Flucytosine but showed least resistance to Micafungin 10%, Caspofungin 10% and 8% to amphotericin-b. More resistance to azole was seen in *C.albicans* and this was comparable to a study conducted by Rajeevan et al.¹⁵

All isolated *C. krusei* were resistance to fluconazole which was comparable to the study done by Mondal et al.¹⁶ *C. krusei* was 67% susceptible to Caspofungin, Micafungin, amphotericin-b, Flucytosine and only 33% susceptible to voriconazole.

C. parapsilosis showed 100% susceptible to Micafungin, Caspofungin, amphotericin-b and Flucytosine. Only some showed resistance to azole group, 9% to voriconazole

and 5% to fluconazole. In contrast Jangla S M et al.¹⁷ found 100% sensitivity to azole group, amphotericin-b, Micafungin, Caspofungin, Flucytosine among all *Candida* species.

C. tropicalis showed 100% susceptibility to Micafungin, amphotericin-b and Caspofungin. But showed 9% resistance to fluconazole & voriconazole, 3% resistance to Flucytosine. *C. dubliniensis* showed 100% susceptible to Micafungin and 91% susceptible to rest of the antifungal drug used in our study.

5. Conclusion

Infection caused by Non albicans *candida* (NAC) species has been increased. *C. tropicalis* was the most common isolated species. *Candida albicans*, *C. glabrata* and *C. krusei* showed high susceptibility to fluconazole and voriconazole. Amphotericin B, Caspofungin, Micafungin and Flucytosine showed high susceptibility towards other candida species.

Our study concluded that VITEK 2 was more accurate and less time consuming as comparative to conventional methods. Identification of *candida* species and their antifungal susceptibility are important for the treatment of immunocompromised patients and patient with serious underlying disease.

6. Conflict of Interest

The authors declare that there are no conflicts of interest in this paper.

7. Source of Funding

Teerthanker Mahaveer University" provided financial support for research work.

References

1. K S, Mangalkar S, Gohel T. Isolation of different Candida Species from Clinical samples and Comparison between Conventional and Hicrome Technique of Identification. *Int J Sci Res*. 2015;4(5):1–5.
2. Kojic EM, Darouiche RO. Candida Infections of Medical Devices. *Clin Microbiol Rev*. 2004;17(2):255–67.
3. Wey SB, Mori MP, Faller MA, Woolson RF, Wenzel RP. Hospital - acquired candidemia. The attributable mortality and excess length of stay. *Arc Inter Med*. 1998;148(12):2642–5.
4. Epstein JB, Komiyama K, Duncan D. Oral topical steroids and secondary oral candidiasis. *J Oral Med*. 1986;14(4):223–7.
5. de Sousa L, Santos VL, Monteiro AS, Monteiro AS, Dias-Souza MV, Marques SG, et al. Isolation and identification of Candida species in patients with orogastric cancer: susceptibility to antifungal drugs, attributes of virulence in vitro and immune response phenotype. *BMC Infect Dis*. 2016;16:86. doi:10.1186/s12879-016-1431-4.
6. Samyukthaa AA, Saikumar C. Isolation, Identification and Speciation of Candida Species from Various Clinical Specimens in a Tertiary Care Hospital in Chennai. *Sch J App Med Sci*. 2017;5(8):3460–8.
7. Devi LS, Maheshwari M. Speciation of Candida Species Isolated from Clinical Specimens by Using Chrom Agar and Conventional Methods. *Inter J Scientific Res Pub*. 2014;4(3):2250–3135.
8. Mehta R, Wyawahare AS. Evaluation of hichrom Candida differential agar for species identification of Candida isolates from various clinical samples. *Int J Contemp Med Res*. 2016;3(4):1219–22.
9. Sundaram M, Navaneethkrishnan. Evaluation of Vitek 2 System for clinical identification of Candida species and their antifungal susceptibility profile. *Evolution Med Den Sci*. 2016;5(47):2278–4748.
10. Shivprakash S, Radhakrishnan K, Karim PMS. Candida species other than *Candida albicans* a major cause of fungemia in a tertiary care centre. *Ind J Med Microbiol*. 2007;25(4):405–7.
11. Leory O. A multicentre study of antifungal strategies and outcome of Candida spp. peritonitis in intensive-care units. *Clin Microbiol and Infec*. 2010;17(7):1061–7.
12. Ahamad I, Farooq U. Isolation and Identification of Candida Species with their Antifungal Susceptibility Profile in a Tertiary Care Hospital. *Eur J Pharma Med Res*. 2019;.
13. Yashavanth R, Shiju MP, Bhaskar UA, Ronald R, Anita KB. Candiduria: Prevalence and Trends in Antifungal Susceptibility in a Tertiary Care Hospital of Mangalore. *J Clin Diagn Res*. 2013;7(11):2459–61.
14. Kauffman CA, Vazquez JA, Sobel JD, Gallis HA, McKinsey DS, Karchmer AW, et al. Prospective multicenter surveillance study of funguria in hospitalized patients. The National Institute for Allergy and Infectious Diseases (NIAID) Mycoses Study Group. *Clin Infect Dis*. 2000;30(1):14–8. doi:10.1086/313583.
15. Rajeevan S, Thomas M, Appalaraju B. Characterisation and antifungal susceptibility pattern of Candida species isolated from various clinical samples at a tertiary care centre in South India. *Indian J Microbiol Res*. 2016;3(1):53–7.
16. Mondal S, Mondal A, Pal N, Banerjee P, Kumar S, Bhargava D, et al. Species distribution and in vitro antifungal susceptibility patterns of Candida. *J Institute Med*. 2013;35(1):45–54.
17. Jangla SM, Naidu R, Patel SC. Speciation and antifungal susceptibility testing of Candida isolates in various clinical samples in a tertiary care hospital in Mumbai. *Int J Biomed Res*. 2018;9(3):106–11.

Author biography

Ayushi Jain, Post Graduate Student  <https://orcid.org/0000-0002-8513-4408>

Umar Farooq, Professor and HOD

Sudhir Singh, Professor

Vasundhara Sharma, Associate Professor

Shweta R Sharma, Associate Professor

Imran Ahamad, Assistant Professor

Cite this article: Jain A, Farooq U, Singh S, Sharma V, Sharma SR, Ahamad I. Frequency of candida infection among intensive care unit patients and their susceptibility profile. *IP Int J Med Microbiol Trop Dis* 2021;7(3):133-136.